| Original language | English (US) |
|---|---|
| Pages (from-to) | 744-746 |
| Number of pages | 3 |
| Journal | Biological Psychiatry |
| Volume | 78 |
| Issue number | 11 |
| DOIs |
|
| State | Published - 2015 |
ASJC Scopus subject areas
- Biological Psychiatry
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Understanding Symbol Coding in Schizophrenia. / Keefe, Richard S.E.; Harvey, Philip D.
In: Biological Psychiatry, Vol. 78, No. 11, 2015, p. 744-746.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Understanding Symbol Coding in Schizophrenia
AU - Keefe, Richard S.E.
AU - Harvey, Philip D.
N1 - Funding Information: RSEK currently or in the past 24 months has received investigator-initiated research funding support from the Department of Veterans Affairs, Feinstein Institute for Medical Research, National Institute of Mental Health, Research Foundation for Mental Hygiene, Inc, and Singapore National Medical Research Council; has received honoraria, served as a consultant, or served as an advisory board member for Abbvie, Akebia, Asubio, Avanir, Avineuro (ChemRar), Biogen Idec, Inc., BioLineRx, Biomarin, Boehringer Ingelheim, FORUM Pharmaceuticals, GW Pharmaceuticals, Janssen Research & Development, Johnson & Johnson, Lundbeck, Merck, Minerva Neurosciences, Inc, Mitsubishi, Novartis, New York State Office of Mental Health, Otsuka, Pfizer, Reviva, Roche, Sanofi/Aventis, Shire, Sunovion, Takeda, Targacept, and the University of Texas South West Medical Center; receives royalties from the Brief Assessment of Cognition in Schizophrenia testing battery, Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (Brief Assessment of Cognition in Schizophrenia Symbol Coding), and Virtual Reality Functional Capacity Assessment Tool; and is a shareholder in NeuroCog Trials, Inc, and SenGenix, Inc. PDH has received consulting fees from Abbvie, Boehringer Ingelheim, Forum Pharma, Genentech, Lundbeck, Otsuka America, Roche Pharma, Sanofi Pharma, Sunovion Pharma, and Takeda Pharma during the past 2 years; received contract research support from Genentech and a research grant from Takeda; and receives royalties from the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery and Brief Assessment of Cognition in Schizophrenia Symbol Coding, referenced in the article.
PY - 2015
Y1 - 2015
UR - http://www.scopus.com/inward/record.url?scp=84960843589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960843589&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2015.09.005
DO - 10.1016/j.biopsych.2015.09.005
M3 - Comment/debate
C2 - 26542742
AN - SCOPUS:84960843589
VL - 78
SP - 744
EP - 746
JO - Biological Psychiatry
JF - Biological Psychiatry
SN - 0006-3223
IS - 11
ER -